Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Nearly 60 Ukrainian therapists will attend the event at no cost, learning fundamentals and best practices for psychedelic-assisted therapiesMore than 300 practitioners from more than 30 countries have...
-
Washington, DC, and Smithtown, NY, April 02, 2025 (GLOBE NEWSWIRE) -- America's VetDogs, a leading national nonprofit provider of service dogs to veterans, active-duty service members, and first...
-
New York, April 02, 2025 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) invites the public to a free webinar, “Developing a Potential New Treatment for Chronic PTSD:...
-
PRESTON, Wash., March 24, 2025 (GLOBE NEWSWIRE) -- Today Sparkling Ice®, crafted by Talking Rain Beverage Company®, reconfirmed its commitment to “saving lives at both ends of the leash” with the...
-
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial for AL001 Treatment of Post-Traumatic Stress Disorder at Massachusetts General Hospital
-
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder at Massachusetts General Hospital
-
PharmAla to supply the STRONG STAR Consortium with new 20mg MDMA dose to treat active-duty military personnel in a clinical trial
-
PharmAla partners with Merhavim and MAPS Israel for innovative MDMA PTSD clinical trial data sharing partnership in wake of Gaza Ceasefire
-
Halberd Update on WatchDawg® PTSD Treatment
-
After three years of negotiation with the FDA, MAPS has successfully secured FDA clearance to conduct a clinical trial, MJP2, to examine the use of smoked cannabis for the treatment of PTSD symptoms...